Quarterly ResultAug 6, 2026, 08:08 AM
Paysign Q2 Revenue +48% to $28.25M; EPS $0.11
AI Summary
Paysign, Inc. reported strong financial results for the second quarter and first half of 2026, with significant increases in revenue and net income. The company's Q2 revenue grew by 48% to $28.25 million, and diluted EPS rose to $0.11. Additionally, Paysign terminated the contingent consideration related to its March 2025 acquisition of Gamma Innovation LLC, with the liability reduced to $0 due to lower-than-expected revenue from acquired technologies.
Key Highlights
- Q2 2026 total revenues increased 48% to $28.25 million from $19.08 million in Q2 2025.
- Q2 2026 diluted earnings per share rose to $0.11, up from $0.02 in Q2 2025.
- Net income for Q2 2026 was $6.76 million, a substantial increase from $1.39 million in Q2 2025.
- Pharma industry revenue for Q2 2026 grew 89% to $14.65 million, while Plasma industry revenue increased 21% to $13.04 million.
- For the six months ended June 30, 2026, total revenues increased 49% to $56.29 million.
- The contingent consideration liability for the Gamma Innovation LLC acquisition was reduced to $0 and terminated.
- Cash and restricted cash totaled $176.48 million as of June 30, 2026, up from $164.98 million at year-end 2025.
Price Impact
More from PAYS